Immuneering Corp — Director's Dealing 2021

Jul 30, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2021-07-29

Reporting Person: Feinberg Peter (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	123753	Indirect
Class A Common Stock	224246	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option	$3.01	2029-12-15	Class A Common Stock (111153)		Direct
Series A Preferred Stock	$		Class A Common Stock (102926)		Indirect
Series A Preferred Stock	$		Class A Common Stock (92509)		Indirect
Series A Preferred Stock	$		Class A Common Stock (51462)		Indirect
Series B Preferred Stock	$		Class A Common Stock (30646)		Indirect
Series B Preferred Stock	$		Class A Common Stock (30646)		Indirect
Series B Preferred Stock	$		Class A Common Stock (30646)		Indirect

Footnotes

F1: Mr. Feinberg is a General Partner of PF Associates L.P.

F2: Mr. Feinberg is a General Partner of PEF LLC.

F3: The option vests and becomes exercisable as to 25% of the underlying shares on December 16, 2020 and then in equal monthly installments over the subsequent three years, subject to Mr. Feinberg's continued service to the Issuer's board of directors through each applicable vesting date.

F4: Each share of the Issuer's preferred stock is convertible on a one-for-one basis into shares of the Issuer's Class A common stock in certain circumstances and has no expiration date. The preferred stock will automatically convert into Class A common stock immediately prior to the closing of the Issuer's initial public offering.

F5: Mr. Feinberg is a General Partner of S4K Investments LLC.